These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35588144)

  • 21. Tumour cell vaccines that secrete interleukin-2 (IL-2) and interferon gamma (IFN gamma) are recognised by T cells while resisting destruction by natural killer (NK) cells.
    Zier KS; Gansbacher B
    Eur J Cancer; 1996 Jul; 32A(8):1408-12. PubMed ID: 8869107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation.
    Jin GH; Hirano T; Murakami M
    Int Immunol; 2008 Jun; 20(6):783-9. PubMed ID: 18448458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
    Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploiting Human NK Cells in Tumor Therapy.
    Vacca P; Pietra G; Tumino N; Munari E; Mingari MC; Moretta L
    Front Immunol; 2019; 10():3013. PubMed ID: 32010130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. STING-induced regulatory B cells compromise NK function in cancer immunity.
    Li S; Mirlekar B; Johnson BM; Brickey WJ; Wrobel JA; Yang N; Song D; Entwistle S; Tan X; Deng M; Cui Y; Li W; Vincent BG; Gale M; Pylayeva-Gupta Y; Ting JP
    Nature; 2022 Oct; 610(7931):373-380. PubMed ID: 36198789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I-Deficient Tumors.
    Seo H; Kim BS; Bae EA; Min BS; Han YD; Shin SJ; Kang CY
    Cancer Immunol Res; 2018 Jun; 6(6):685-695. PubMed ID: 29615398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
    Morrison BJ; Steel JC; Morris JC
    BMC Cancer; 2018 Apr; 18(1):469. PubMed ID: 29699516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
    Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
    Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of photodynamic therapy on tumor cell expression of major histocompatibility complex (MHC) class I and MHC class I-related molecules.
    Belicha-Villanueva A; Riddell J; Bangia N; Gollnick SO
    Lasers Surg Med; 2012 Jan; 44(1):60-8. PubMed ID: 22246985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
    Homma S; Komita H; Sagawa Y; Ohno T; Toda G
    Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of BI 7446: A Potent Cyclic Dinucleotide STING Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer.
    Kuttruff CA; Fleck M; Carotta S; Arnhof H; Bretschneider T; Dahmann G; Gremel G; Grube A; Handschuh S; Heimann A; Hofmann MH; Impagnatiello MA; Nar H; Rast G; Schaaf O; Schmidt E; Oost T
    J Med Chem; 2023 Jul; 66(14):9376-9400. PubMed ID: 37450324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
    Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
    Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer.
    Da Y; Liu Y; Hu Y; Liu W; Ma J; Lu N; Zhang C; Zhang C
    Oncoimmunology; 2022; 11(1):2054105. PubMed ID: 35371622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
    Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
    J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD4 cells can be more efficient at tumor rejection than CD8 cells.
    Perez-Diez A; Joncker NT; Choi K; Chan WF; Anderson CC; Lantz O; Matzinger P
    Blood; 2007 Jun; 109(12):5346-54. PubMed ID: 17327412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of cancer vaccine with CD122-biased IL-2/anti-IL-2 Ab complex shapes the stem-like effector NK and CD8
    Shimizu K; Ueda S; Kawamura M; Aoshima H; Satoh M; Nakabayashi J; Fujii SI
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37400134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.